Jefferies Says Watch for Bottom in Endo Pharma (ENDP)

Article Related Press Releases (1) Related Articles (1) Stock Quotes (1) Comments (0)

Jefferies maintained a Buy on Endo Pharmaceuticals Holdings Inc (NASDAQ: ENDP) but cut its price target of $36.00 (from $42.00) in the wake of the company’s weak Q3 earnings report and lower guidance.

"Sentiment couldn't get much worse now, and [Monday's] selling may be a signal for the bottom, but we lower our target to $36 given the miscue," said analyst Corey Davis.

With sentiment at all-time lows, he sees positive risk-reward in the stock.

For an analyst ratings summary and ratings history on Endo Pharmaceuticals Holdings Inc click here. For more ratings news on Endo Pharmaceuticals Holdings Inc click here.

Shares of Endo Pharmaceuticals Holdings Inc closed at $26.73 yesterday, with a 52 week range of $26.70-$39.29.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UPDATE: Wedbush Downgrades XenoPort (XNPT) to Neutral
• Goldman Sachs Downgrades Thoratec (THOR) to Neutral
• Jefferies Raises PT on Aeropostale (ARO) Ahead of Q1

Create E-mail Alert Related Categories

Analyst Comments, Analyst EPS View, Analyst PT Change

Related Entities

Jefferies & Co, Earnings

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?